NEW BLOG POST! Check out the latest edition of our 'RARE' blog series by our Principal Consultant, Laura Hulley. On this episode of RARE, Laura welcomed Tomas Baldwin, Co-Founder and CEO of the UCL-spin out Guilford Street Laboratories. A company that was created to advance the state of diagnostics in healthcare, particularly for those suffering with rare, cardiac and neurodegenerative diseases. Read the blog and watch the full interview through the link below 👇 https://lnkd.in/evGFMZqR #RareDiseases #RareDiseaseAwareness #Blog
SciPro’s Post
More Relevant Posts
-
Reisa Sperling, MD, Chris Van Dyck, MD, Dennis Selkoe, MD, and Larisa Reyderman, PhD, will be sharing our latest Alzheimer’s disease (AD) clinical data in Hall A today at #AAIC24 at 4:15 PM ET. Join us to hear the latest updates. #AlzheimersDisease #EndAlz
To view or add a comment, sign in
-
Are you, too, heading for AD/PD 2024 in Lisbon, Portugal? 👋 Come meet our #teamfujirebio with experts from Marketing, Sales and R&D (see comments 👇 for details) who are eager to discuss the latest within the field of neurodegenerative disease testing - find us at booth 6 👉 https://lnkd.in/eMZcHtum #ADPD #neurodegeneration #alzheimersdisease #parkinsonsdisease
To view or add a comment, sign in
-
Great articles from our colleagues in DTI, Dementia Trials Ireland. 👇 The prevalence and consequence of various forms of #dementia, inc. #Alzheimer's disease, is growing in Ireland and globally. However, new biomedical insight is helping drive enormous diagnostic and treatment opportunities where #clinicaltrials and #research is, and will, open up better pathways for diagnosis, management and outcome improvement; giving hope to those impacted and driving further improvements in care. The national network of DTI, Dementia Trials Ireland provides a great opportunity for Ireland to play a leading role in informing and driving advances in this rapidly evolving field. 👏
3 recent key publications (DTI members and colleagues) on the advent of Disease Modifying Therapies for Alzheimer's disease. Paper focus and links below. 1. Diagnosis and management: https://lnkd.in/gs4S-Cay 2. Stakeholder acceptance and willingness to pay: https://lnkd.in/gQujUszj 3. Service model for DMT delivery: https://lnkd.in/gcqKR-PD
To view or add a comment, sign in
-
April is Parkinson's Awareness Month! 🤍 This special month aims to raise awareness on #ParkinsonsDisease and recognize its symptoms or early signs that can lead to an earlier diagnosis and overall better quality of life! Start learning more about Parkinson's Disease this month to spread the word and advance PD research. Check out our currently open Parkinson's clinical trials conducted by our Principal Investigators, Dr. Anna Morenkova and Dr. Nicolas Phielipp: https://bit.ly/3MDKIiG
To view or add a comment, sign in
-
EFNA President, Astri Arnesen, spoke to BestPractice Nordic DK about the importance of disease-specific patient journeys for Huntington’s disease and other neurological conditions. These patient journeys, developed by the ERN-RND, European Reference Network for Rare Neurological Diseases describe the complexity of the diseases and what the healthcare system and the patients should be aware of. https://lnkd.in/eRXNGB8Z
Disease-Specific Patient Journeys for Huntington's Disease
https://bpno.no
To view or add a comment, sign in
-
Thanks MIT School of Engineering for covering my research!
Yuzhe Yang is a Takeda Fellow in MIT EECS who is developing an AI-based diagnosis model for Parkinson's Disease (PD) and Alzheimer’s Disease (AD) using sleep-breathing data that is significantly more reliable, flexible, and economical than current diagnostic tools. His passive, in-home, contactless monitoring system—resembling a simple home Wi-Fi router—will also enable remote disease assessment and continuous progression tracking. Yuzhe’s work has the potential to advance the diagnosis and treatment of prevalent diseases like PD and AD, and offers exciting possibilities for addressing many health challenges with reliable, affordable machine-learning tools.
To view or add a comment, sign in
-
I am thrilled to announce that my research paper titled "Utilizing Machine Learning Approaches for Cardiovascular Disease Forecasting" has been published by IEEE! Heart disease remains the leading cause of death worldwide, and early detection is crucial for effective treatment. In our study, we explored various machine learning techniques to predict the probability of individuals developing coronary heart disease within ten years. This research aims to aid healthcare providers in making more precise, trustworthy, and swift diagnoses, ultimately contributing to better patient outcomes. For those interested in a deeper dive into our methodology and results, you can read the full paper here: https://lnkd.in/g-kzk72q #Research #MachineLearning #CardiovascularDisease #HealthcareInnovation #DataScience #AcademicPublication #IEEE
Utilizing Machine Learning Approaches for Cardiovascular Disease Forecasting
ieeexplore.ieee.org
To view or add a comment, sign in
-
There have been great strides in Alzheimer’s disease (AD) research. During World Alzheimer’s Month, we’re highlighting the need to do even more to improve care for people living with AD. Learn more here: https://bit.ly/3GDVQsk #AlzheimersDisease #WorldAlzMonth #TimeToActOnAlzheimers
Explore our commitment to AD research
us.eisai.com
To view or add a comment, sign in
-
We were delighted to introduce InRAD, an international, practice-based registry for Alzheimer's Disease and other dementias at the EADC (European Alzheimer's Disease Consortium) annual meeting yesterday. One of our founding Board members, Frank Jessen, explained how InRAD can help address pressing questions about the clinical management of Alzheimer's disease, enable large study collaborations with a common minimum data set and facilitate a wide range of sub-studies on a global scale. Click here to find out more about InRAD and join our effort to accelerate progress in Alzheimer's practice-based research: https://lnkd.in/gGDTvs6i #InRAD #AlzheimersResearch #GlobalImpact #EADC #RealWorldData #AlzheimersRegistry
To view or add a comment, sign in
-
Astri Arnesen, the President of the European Federation of Neurological Associations, focuses in this MEDtalk on the importance of disease-specific patient journeys for Huntington's disease. In these patient journeys, the development of the European Reference Network for rare neurological diseases describes the complexity and what the healthcare system and the patients should be aware of. 🔗Follow along as we cover the EAN 2024 congress; https://lnkd.in/dzTEGiny #EAN24
Disease-Specific Patient Journeys for Huntington's Disease
https://bpno.no
To view or add a comment, sign in
95,097 followers